Rhythm Pharmaceuticals Inc (RYTM)
40.98
-0.45
(-1.09%)
USD |
NASDAQ |
May 02, 16:00
40.98
0.00 (0.00%)
After-Hours: 19:56
Rhythm Pharmaceuticals Enterprise Value: 2.250B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 2.250B |
| April 30, 2024 | 2.148B |
| April 29, 2024 | 2.091B |
| April 26, 2024 | 2.058B |
| April 25, 2024 | 2.050B |
| April 24, 2024 | 2.145B |
| April 23, 2024 | 2.163B |
| April 22, 2024 | 2.103B |
| April 19, 2024 | 2.010B |
| April 18, 2024 | 2.016B |
| April 17, 2024 | 2.037B |
| April 16, 2024 | 2.041B |
| April 15, 2024 | 2.135B |
| April 12, 2024 | 2.150B |
| April 11, 2024 | 2.285B |
| April 10, 2024 | 2.196B |
| April 09, 2024 | 2.347B |
| April 08, 2024 | 2.238B |
| April 05, 2024 | 2.162B |
| April 04, 2024 | 2.136B |
| April 03, 2024 | 2.183B |
| April 02, 2024 | 2.133B |
| April 01, 2024 | 2.291B |
| March 28, 2024 | 2.330B |
| March 27, 2024 | 2.237B |
| Date | Value |
|---|---|
| March 26, 2024 | 2.102B |
| March 25, 2024 | 2.109B |
| March 22, 2024 | 2.163B |
| March 21, 2024 | 2.168B |
| March 20, 2024 | 2.111B |
| March 19, 2024 | 2.077B |
| March 18, 2024 | 2.166B |
| March 15, 2024 | 2.130B |
| March 14, 2024 | 2.131B |
| March 13, 2024 | 2.188B |
| March 12, 2024 | 2.141B |
| March 11, 2024 | 2.160B |
| March 08, 2024 | 2.246B |
| March 07, 2024 | 2.230B |
| March 06, 2024 | 2.196B |
| March 05, 2024 | 2.204B |
| March 04, 2024 | 2.257B |
| March 01, 2024 | 2.353B |
| February 29, 2024 | 2.335B |
| February 28, 2024 | 2.393B |
| February 27, 2024 | 2.492B |
| February 26, 2024 | 2.500B |
| February 23, 2024 | 2.440B |
| February 22, 2024 | 2.342B |
| February 21, 2024 | 2.625B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-83.74M
Minimum
May 19 2022
2.840B
Maximum
Feb 12 2024
826.25M
Average
697.99M
Median
Enterprise Value Benchmarks
| Pfizer Inc | 211.91B |
| Insmed Inc | 4.172B |
| Altimmune Inc | 303.41M |
| Regeneron Pharmaceuticals Inc | 90.26B |
| Viking Therapeutics Inc | 7.465B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.63M |
| Revenue (Quarterly) | 24.23M |
| Total Expenses (Quarterly) | 65.50M |
| EPS Diluted (Quarterly) | -0.70 |
| Gross Profit Margin (Quarterly) | 86.66% |
| Profit Margin (Quarterly) | -171.8% |
| Earnings Yield | -7.81% |
| Normalized Earnings Yield | -7.809 |